Zogenix and Battelle to Present Positive, New Data Demonstrating Value of Needle-Free Injection for Biologics

Zogenix and Battelle to Present Positive, New Data Demonstrating Value of
Needle-Free Injection for Biologics

DosePro Studies to be Presented at 2013 AAPS National Biotechnology Conference

SAN DIEGO and COLUMBUS, Ohio, May 20, 2013 (GLOBE NEWSWIRE) -- Zogenix, Inc.
(Nasdaq:ZGNX) and Battelle Memorial Institute today announced new data
supporting the value of the DosePro® needle-free injection technology in the
delivery of biologics. The positive, new data will be presented in four poster
presentations, including two posters co-authored by MedImmune, LLC, the
worldwide biologics research and development arm of AstraZeneca plc, and
Zogenix; and two posters co-authored by Battelle and Zogenix, at the 2013
American Association of Pharmaceutical Scientists (AAPS) National
Biotechnology Conference, May 20-22, 2013 in San Diego.

The data presented in these posters show that the DosePro technology is
compatible with monoclonal antibodies formulations and a range of biologic
formulation viscosities which are challenging to deliver via standard
autoinjector technologies. The studies found that injection of these
formulations were within the acceptable criteria for injection time and peak
pressure and that there were no changes in molecular integrity, observable
tertiary structure, purity or potency following injection. The data also show
that needle-free technology such as DosePro has the potential to positively
impact patient acceptance of self-injectable therapies, leading to greater
adoption and adherence of subcutaneously administered biologics.

John Turanin, Vice President and General Manager, DosePro Technology, at
Zogenix, commented, "This new data represents an important step in addressing
the need for delivery technology for biologics by demonstrating DosePro's
compatibility with the viscous formulations and the impact of needle-free
delivery on patient confidence. We believe the AAPS National Biotechnology
Conference will be an excellent forum to introduce the DosePro system to
potential biopharmaceutical partners looking for innovative delivery
technology solutions for their current and future self-injection therapies."

The four posters to be presented at the AAPS National Biotechnology Conference

  *In Vitro Integrity of Two Recombinant Human Monoclonal Antibodies after
    Instantaneous Injection by DosePro® Delivery Technology; Poster# M1012
  *Injection Performance Assessment of Monoclonal Antibody Formulation
    Viscosity mimics Using an Instantaneous Injection Technology; Poster#
  *Adoption, Adherence, and Preferences Regarding Injectable Drug Delivery by
    Patients with Rheumatoid Arthritis: Results of a Research Survey; Poster#
  *Devices for Delivery of Viscous Protein Formulations and their Impact on
    Protein Structure; Poster# T2012

Battelle will feature the DosePro system at its booth (#413) at the AAPS
National Biotechnology Conference. For more information on licensing
opportunities using the DosePro platform contact Battelle at 1-800-201-2011 or

About DosePro®

The DosePro system is a first-in-class, easy-to-use drug delivery system
designed for self-administration of a pre-filled, single dose of sterile
liquid drug, subcutaneously, without a needle. The platform is currently used
by Zogenix's first commercial product, SUMAVEL DosePro^®. The Company believes
that DosePro offers several benefits to patients compared to other
subcutaneous needle-based delivery methods, and that it has the potential to
become a preferred delivery option for patients and physicians. These benefits
include less anxiety or fear due to the lack of a needle, easier disposal
without the need for a sharps container, no risk of needle stick injury or
contamination, an easy-to-use three step administration process, no need to
fill the device prior to use, reliable performance, discreet use and
portability. In several clinical trials and market research studies, DosePro
has been shown to be preferred by patients over conventional needle-based

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville,
California, is a pharmaceutical company commercializing and developing
products for the treatment of central nervous system disorders and pain.
Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection)
Needle-free Delivery System, was launched in January 2010 for the acute
treatment of migraine and cluster headache. Zogenix's lead investigational
product candidate, Zohydro™ ER (hydrocodone bitartrate), is an oral,
extended-release formulation of various strengths of hydrocodone, without
acetaminophen, intended for administration every 12 hours for around the clock
management of moderate to severe chronic pain. In May 2012, Zogenix submitted
to the FDA a New Drug Application for Zohydro ER. Zogenix's second
investigational product candidate, Relday™, is a proprietary, long-acting
injectable formulation of risperidone for the treatment of schizophrenia; an
investigational new drug application was submitted to the FDA in May 2012.

About Battelle

Every day, the people of Battelle apply science and technology to solving what
matters most. At major technology centers and national laboratories around the
world, Battelle conducts research and development, designs and manufactures
products, and delivers critical services for government and commercial
customers. Headquartered in Columbus, Ohio since its founding in 1929,
Battelle serves the national security, health and life sciences, and energy
and environmental industries. For more information, visit www.battelle.org.

Forward-Looking Statements

Zogenix cautions you that statements included in this press release that are
not a description of historical facts are forward-looking statements. Words
such as "believes," "anticipates," "plans," "expects," "indicates," "will,"
"intends," "potential," "suggests," "assuming," "designed" and similar
expressions are intended to identify forward-looking statements. These
statements are based on the company's current beliefs and expectations. These
forward-looking statements include statements regarding the potential benefits
of needle-free technology such as DosePro and the potential to partner the
DosePro technology with biopharmaceutical companies. The inclusion of
forward-looking statements should not be regarded as a representation by
Zogenix that any of its plans will be achieved. Actual results may differ from
those set forth in this press release due to the risk and uncertainties
inherent in Zogenix's business, including, without limitation: difficulties in
identifying, negotiating, executing and carrying out strategic transactions
relating to DosePro and obtaining regulatory approval for other DosePro
products; risks associated with the development of a larger volume, second
generation version of the DosePro technology to accommodate drug formulation
volumes greater than 0.5 mL; the potential that earlier pre-clinical studies
may not be predictive of future pre-clinical or clinical results; and the
scope, validity and duration of patent protection and other intellectual
property rights for DosePro; the impact of any inability to raise sufficient
capital to fund ongoing operations; and other risks described in Zogenix's
filings with the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only as
of the date hereof, and Zogenix undertakes no obligation to revise or update
this press release to reflect events or circumstances after the date hereof.
All forward-looking statements are qualified in their entirety by this
cautionary statement. This caution is made under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995.

SUMAVEL^®, DosePro^®, Relday^TM and Zohydro^TM ER are trademarks of Zogenix,

SODAS^® is a trademark of Alkermes Pharma Ireland Limited.


CONTACT: Zogenix Contacts:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com
         Caitlin Cox | The Ruth Group
         646.536.7033 | ccox@theruthgroup.com
         Battelle Contacts:
         Katy Delaney
         614.424.7208 | delaneyk@battelle.org
         T.R. Massey
         614.424.5544 | masseytr@battelle.org
Press spacebar to pause and continue. Press esc to stop.